Here, we report a phase I study of cancer vaccination using a combination of two multi-HLA-binding peptides, HSP70 and GPC3, and the novel immune adjuvants combination of Poly-ICLC and hLAG-3Ig for patients with metastatic GI cancers. Here, HLA-G is linked to cancer.